Recursion Pharmaceuticals has announced a major regulatory milestone, revealing on November 18, 2026 that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a planned Phase 3 clinical trial for its investigational drug REC-4881. This step marks a significant advance in the development of the potential therapy for familial adenomatous polyposis (FAP), an inherited condition that predisposes individuals to colorectal and other gastrointestinal cancers.

REC-4881, discovered using Recursion’s AI-enabled drug discovery platform, is one of the few late-stage experimental therapies targeting FAP, a disease affecting over 50,000 patients across the U.S. and European Union’s five largest countries. Currently, there are no approved pharmaceutical therapies for FAP, leaving patients with limited options beyond repeated surgeries to manage polyp growth and cancer risk. The orphan drug and fast track designations previously awarded to REC-4881 by the FDA highlight the agency’s recognition of this underserved patient population.

The new alignment between Recursion and the FDA establishes the parameters for the Phase 3 trial, which will evaluate the efficacy and safety of REC-4881 in adults with FAP. The trial is slated to begin enrollment in the second half of 2027. According to Recursion’s regulatory filings and investor disclosures, earlier trials showed promising signs: in the TUPELO Phase 1b/2 study, FAP patients treated with REC-4881 experienced a median 47% reduction in total polyp burden after 12 weeks, with some achieving even greater decreases. This earlier data underpins optimism for the more comprehensive Phase 3 effort.

The immediate financial response underscored the development’s perceived importance. Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) finished November 18 at $2.83, gaining nearly 4% with trading volumes rising sharply above recent averages. The company also highlighted its robust cash position—approximately $749 million following a recent stock offering—giving Recursion a projected financial runway into 2029. This ensures the company is well-capitalized to conduct its long-duration clinical plans.

Recursion further bolstered its leadership in late October by appointing veteran pharmaceutical executive Fred Hassan as Chair of the Board, signaling strategic focus as the company enters a critical period. While the outcome of the forthcoming Phase 3 trial will ultimately determine the clinical and commercial fate of REC-4881, achieving FDA design alignment marks a critical point in the long path from laboratory discovery to possible new therapy for a rare and life-altering disease.

No therapies are currently approved for the treatment of FAP, yet the disease represents a sizable market need—estimated by some analysts at over $15 billion—should REC-4881 or another investigational drug eventually achieve regulatory success. The future of FAP treatment now hinges on the results of this next pivotal study, with Recursion poised to provide updates as work progresses toward trial initiation in 2027.